JP2025501239A5 - - Google Patents

Info

Publication number
JP2025501239A5
JP2025501239A5 JP2024539527A JP2024539527A JP2025501239A5 JP 2025501239 A5 JP2025501239 A5 JP 2025501239A5 JP 2024539527 A JP2024539527 A JP 2024539527A JP 2024539527 A JP2024539527 A JP 2024539527A JP 2025501239 A5 JP2025501239 A5 JP 2025501239A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antagonist
subject
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501239A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082535 external-priority patent/WO2023130010A1/en
Publication of JP2025501239A publication Critical patent/JP2025501239A/ja
Publication of JP2025501239A5 publication Critical patent/JP2025501239A5/ja
Pending legal-status Critical Current

Links

JP2024539527A 2021-12-30 2022-12-29 Il-4/il-13アンタゴニストを投与することによってアトピーマーチを減弱する方法 Pending JP2025501239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295113P 2021-12-30 2021-12-30
US63/295,113 2021-12-30
PCT/US2022/082535 WO2023130010A1 (en) 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Publications (2)

Publication Number Publication Date
JP2025501239A JP2025501239A (ja) 2025-01-17
JP2025501239A5 true JP2025501239A5 (enExample) 2026-01-09

Family

ID=85199428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539527A Pending JP2025501239A (ja) 2021-12-30 2022-12-29 Il-4/il-13アンタゴニストを投与することによってアトピーマーチを減弱する方法

Country Status (10)

Country Link
US (1) US20230220089A1 (enExample)
EP (1) EP4457245A1 (enExample)
JP (1) JP2025501239A (enExample)
KR (1) KR20240135618A (enExample)
CN (1) CN118355034A (enExample)
AU (1) AU2022425608A1 (enExample)
CA (1) CA3241374A1 (enExample)
IL (1) IL313897A (enExample)
MX (1) MX2024006053A (enExample)
WO (1) WO2023130010A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック, インコーポレイテッド 新規抗il13モノクローナル抗体での癌の処置
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
AU2007228943B2 (en) 2006-03-22 2012-03-22 Apogenix Gmbh Antibody specific for human IL-4 for the treament of cancer
PL3339445T3 (pl) 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
CN103328506A (zh) 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
KR102576903B1 (ko) * 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
HK1220919A1 (zh) 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器(二)
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器(二)
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置(五)
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN113166259A (zh) 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
CN111686247B (zh) 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN112010977B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
KR20220158821A (ko) * 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
TW202216782A (zh) 2020-09-10 2022-05-01 大陸商舒泰神(北京)生物製藥股份有限公司 特異性識別白細胞介素—4受體α的抗體及其用途
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
JP7846119B2 (ja) 2020-12-23 2026-04-14 ヌマブ セラピューティクス アクチェンゲゼルシャフト Il-4rに結合する抗体可変ドメイン

Similar Documents

Publication Publication Date Title
JP2022543612A5 (enExample)
US20240199751A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CN105517570B (zh) 通过施用il-4r拮抗剂治疗鼻息肉症的方法
JP2025172841A5 (enExample)
JP2021523188A5 (enExample)
JP2023520676A5 (enExample)
JP2022543815A5 (enExample)
JP2024502471A5 (enExample)
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
TW202106334A (zh) 藉由投予il-33拮抗劑治療或預防哮喘之方法
JP2024532263A5 (enExample)
CN115697378A (zh) 用cgrp抑制剂治疗肺部损伤的方法
JP2023531968A5 (enExample)
CN118355034A (zh) 施用il-4/il-13拮抗剂以减弱特应性进程的方法
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
RU2024121393A (ru) Способы ослабления атопического марша посредством введения антагониста il-4/il-13
RU2024107446A (ru) Способы лечения атопического дерматита посредством введения антагониста il-4r
JP6923594B2 (ja) Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
RU2022105374A (ru) Способы лечения атопического дерматита посредством введения антагониста il-4r
RU2020140639A (ru) Способы лечения атопического дерматита посредством введения ингибитора ил-4r
HK40076109A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
HK40106058A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2024077113A1 (en) Methods of treating fatigue in ulcerative colitis